In this issue:
Molecular classification of bladder cancer
Biomarker-directed study investigates durvalumab plus targeted therapies in MIBC
Promising activity for belzutifan in advanced clear cell RCC.
TROPHY-U-01 results lead to approval of sacituzumab govitecan for refractory UC
TITAN: apalutamide confers survival benefit in castration-sensitive prostate cancer
IMvigor010: no DFS benefit to adjuvant atezolizumab in high-risk MIBC
REMARCC score for prediction of mortality following nephrectomy
Robot-assisted versus open radical cystectomy in bladder cancer
Cost-effectiveness analysis of pembrolizumab in bladder cancer
Adjuvant radiotherapy in node positive prostate cancer patients
Please login below to download this issue (PDF)